Product And PipeLine

TYRIAQ Pharmaceuticals is actively developing a robust pipeline of therapeutic candidates.
We are dedicated to advancing these candidates through rigorous clinical testing and regulatory approval processes to ensure safety and efficacy.

Diabetes

TYR-D001 is a novel formulation that enables effective and sustained control of key antidiabetic agents.

  • TYR-D002 is in progress as a combination dosage with stabilizers to bring sugar levels very close to adherence through once-daily administration.

  • TYR-D002 is a novel Fixed Dose Combination for people with diabetes that makes it easy to manage with a once-daily tablet.

  • TYR-D002 aims to improve outcomes of people with diabetes by maximizing efficacy without adding burden to start life by having multiple doses everyday.

Cardiology

TYR-C001 is a novel Fixed Dose Combination that brings 2 key ingredients together in one pill for people with cardiac diseases.

  • TYR-C001 aims to improve outcomes of people with cardiac diseases by maximizing efficacy and improving compliance.

  • TYR-C002 is a novel triple therapy for people with cardiac diseases.

  • TYR-C002 aims to address different unmet needs in cardiac disease through administration of one simple pill that maximizes efficacy and patient compliance.

Dyslipidaemia

TYR-L001 is a novel lipid therapy for people with Dyslipidemia.

  • TYR-L001 aims to increase total lipid profile through administration of one simple pill.

Urology

TYR-U001 is a novel dual therapy for people with Benign Prostate Hyperplasia.

  • TYR-U001 aims to maximize outcomes by addressing 2 key needs at once — urinary symptoms and prostate health.

TYR-U002 is a novel Fixed Dose Combination for people with erectile dysfunction and premature ejaculation.
TYR-U002 aims to address two common challenges for sexual health in men through a single oral pill.

Scroll to Top